Sarepta Therapeutics
SRPT
345 hedge funds and large institutions have $9.89B invested in Sarepta Therapeutics in 2018 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 114 increasing their positions, 107 reducing their positions, and 45 closing their positions.
60% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 45
33% more call options, than puts
Call options by funds: $444M | Put options by funds: $334M
25% more capital invested
Capital invested by funds: $7.9B → $9.89B (+$1.99B)
8% more funds holding
Funds holding: 318 → 345 (+27)
7% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 107
0.68% more ownership
Funds ownership: 91.5% → 92.18% (+0.68%)
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$260M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$98.9M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$56.2M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$55.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$55.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$90.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$63.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$57.5M |
| 4 |
Renaissance Technologies
New York
|
-$53M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$49.6M |
SRPT Hedge Fund Activity: Q3 2018 in Review
345 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2018, worth a combined $9.89B — up 25% from $7.9B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new SRPT positions and 45 closed out — a net gain of 27 holders — while 114 added to existing stakes and 107 trimmed.
The largest buyer was Sands Capital Management, opening a new position worth an estimated $260M. The largest seller was RTW Investments, cutting an estimated $90.8M.
- 345 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2018, up from 318 in Q2 2018.
- Funds reported $9.89B of Sarepta Therapeutics stock for Q3 2018, up 25% quarter-over-quarter.
- 72 funds opened new Sarepta Therapeutics positions in Q3 2018 and 45 closed out, a net change of +27 holders.
- The largest Sarepta Therapeutics buyer in Q3 2018 was Sands Capital Management, an estimated $260M added.
- The largest Sarepta Therapeutics seller in Q3 2018 was RTW Investments, an estimated $90.8M sold.
Based on aggregated 13F filings for Q3 2018.